Bioavailability Drug Delivery Marketing 
XTalks
NOVEMBER 6, 2024
per share, the offering included 1,300,000 ordinary shares, which began trading on the Nasdaq Global Market under the ticker symbol GELS on October 29, 2024. The stable gel matrix holds multiple ingredients, offering targeted release and enhanced bioavailability while optimizing patient experience. Priced at $4.0
FDA Law Blog
JULY 23, 2024
FDA recently released a much-anticipated draft guidance to address these frequent questions: Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products. Drug delivery includes successful product preparation and the initiation, progression, and completion of dose delivery.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
MARCH 1, 2022
Interestingly, over the past few years, drug developers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration.
Roots Analysis
MAY 21, 2024
Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.
Roots Analysis
OCTOBER 2, 2023
Owing to their unique size and physicochemical properties ( surface roughness, surface area, surface energy, crystal structure and shape ), nanoparticles can be widely used as a contrasting agent in medical imaging, a vesicle to cross the blood-brain barrier and a carrier for targeted delivery of genes / drugs, proteins, vaccines and antibiotics.
Roots Analysis
MARCH 2, 2022
However, it is important to highlight that there are still several challenges which need to be addressed in order to develop biologic drugs capable of effectively being administered via the oral route without undergoing significant losses in specificity and / or bioavailability. Oral Protein / Peptide-based Drugs. Web: [link].
Roots Analysis
FEBRUARY 20, 2022
Over the last decade, one of the major challenges faced by pharmaceutical players across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Nanoparticles Contract Manufacturing. Web: [link].
Expert insights. Personalized for you.
104 
Let's personalize your content